Lead Product(s): Sotorasib
Therapeutic Area: Oncology Product Name: Lumakras
Highest Development Status: Approved Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 28, 2021
QIAGEN’s therascreen KRAS Kit was used to support the CodeBreaK 100 clinical trial of sotorasib and the expansion of the Kit’s CDx claims to include identification of the KRAS G12C mutation in NSCLC samples has been co-approved with LUMAKRAS by the FDA.
Lead Product(s): Avelumab
Therapeutic Area: Oncology Product Name: Bavencio
Highest Development Status: Approved Product Type: Large molecule
Partner/Sponsor/Collaborator: 4D Pharma
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration February 08, 2021
4D pharma intends to commence a clinical trial in 2021 to evaluate BAVENCIO in combination with MRx0518 as a first-line maintenance therapy for locally advanced or metastatic urothelial carcinoma that has not progressed with first-line platinum-containing chemotherapy.